Immunotherapy-Chemo cocktail aims to boost esophageal cancer surgery success
NCT ID NCT07638436
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial is testing whether combining the immunotherapy drug adebrelimab with two chemotherapy drugs (nab-paclitaxel and carboplatin) before surgery can help patients with borderline resectable esophageal cancer. The goal is to increase the chance of completely removing the tumor during surgery, which may lower the risk of the cancer coming back and improve survival. The study will enroll 42 adults with a specific type of esophageal cancer who have not had prior chemotherapy or radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adebrelimab (an immunotherapy drug) combined with nab-paclitaxel and carboplatin (chemotherapy drugs)
- What this could lead to
- If successful, this approach could help more patients with borderline resectable esophageal cancer have complete tumor removal during surgery, potentially reducing recurrence and improving survival.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply broadly. The combination therapy may cause significant side effects, and it is not yet known if it will outperform standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 651 Dongfeng East Road, Guangzhou
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return